Sharika Life Science Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-11-2024
- Paid Up Capital ₹ 2.11 M
as on 16-11-2024
- Company Age 16 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -12.91%
(FY 2023)
- Profit -22.58%
(FY 2023)
- Ebitda -9.76%
(FY 2023)
- Net Worth 13.23%
(FY 2023)
- Total Assets 21.67%
(FY 2023)
About Sharika Life Science
The Corporate was formerly known as Sharika Interlinks Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.11 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Bali, Vijay Trisil, and Rajpal Chauhan serve as directors at the Company.
- CIN/LLPIN
U51109MH2008PLC179940
- Company No.
179940
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sharika Life Science Limited offer?
Sharika Life Science Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Chemical Compound, Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at Sharika Life Science?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Bali  | Director | 11-Mar-2008 | Current |
| Vijay Trisil | Director | 26-Mar-2018 | Current |
| Rajpal Chauhan | Director | 01-Aug-2013 | Current |
Financial Performance of Sharika Life Science.
Sharika Life Science Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.91% decrease. The company also saw a substantial fall in profitability, with a 22.58% decrease in profit. The company's net worth Soared by an impressive increase of 13.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sharika Life Science?
In 2023, Sharika Life Science had a promoter holding of 33.20% and a public holding of 66.80%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sharika Life Science?
Sharika Life Science has a workforce of 38 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sharika Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sharika Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
